Art has over 40 years of operating experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life science companies. Art founded Pappas Capital in 1994, and over the past twenty-seven years the firm has managed more than $750 million in capital and invested in more than 85 life science companies through its flagship Pappas Ventures business unit, as well as its Specialized Fund Management business unit.

Art currently serves as a director for Sorriso Pharmaceuticals and OrphoMed, and as a board observer for Real Endpoints. Prior to founding Pappas Capital, Art held senior level leadership positions at several multinational pharmaceutical companies where he was responsible for the development, licensing and launch of a number of global products. He was an executive member of the board of directors of Glaxo Holdings plc (NYSE: GLX, now GSK), and served as Glaxo’s chief executive responsible for international operations including research, development and manufacturing. Prior to Glaxo, Art was Vice President of Commercial Operations for Abbott International, and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. He previously served as Chairman and founding CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD) (acquired by Eli Lilly), and as a director for Aura Biosciences, Reneo Pharmaceuticals (NASDAQ: RPHM), Afferent Pharmaceuticals (acquired by Merck), Arix Bioscience, Chimerix (NASDAQ: CMRX), TYRX (acquired by Medtronic), Quintiles Transnational Corp. (NASDAQ: QTRN, now NASDAQ: IQV), Syntonix Pharmaceuticals (acquired by Biogen IDEC), LEAD Therapeutics (acquired by BioMarin), and Embrex (NASDAQ: EMBX) (acquired by Pfizer). He also served as a board observer for Amplyx Pharmaceuticals (acquired by Pfizer), Balance Therapeutics, Kezar Life Sciences (NASDAQ: KZR), Milestone Pharmaceuticals (NASDAQ: MIST) and Plexxikon (acquired by Daiichi Sankyo).

Art is a member of the Board of Directors of the North Carolina Biotechnology Center, where he previously served as chair, and the Medical University of South Carolina Foundation for Research Development. He is a member of the Board of Trustees of The Wistar Institute (a National Cancer Institute center) and the Ronald McDonald House of Durham & Wake, the Board of Advisors of the Duke Cancer Institute (a National Cancer Institute center), and the Advisory Board of the BioExec Institute. He is also a member of BayHelix, a China-based organization of global life science community leaders. He previously served on the Board of Directors of the National Venture Capital Association, and as a member of the CEO Roundtable on Cancer. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center.

Art has a clear passion for developing and mentoring entrepreneurs and helping them build great companies. His relationships are broad and deep and he nurtures them as he does his family and friends.


Ohio State University (BS in Biology)
Xavier University (MBA in Finance)